权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Exploiting public genomic and transcriptomic data to uncover cancer-RNA editing relationships

利用公共基因组和转录组数据揭示癌症-RNA 编辑关系

基本信息

批准号：
10453867
负责人：
Xinshu Grace Xiao
金额：
$ 39万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10453867
关键词：
3&apos Untranslated Regions ADAR1 Address Adenosine Affect Amino Acid Sequence Base Sequence Bioinformatics Cancer Control Cancer Patient Cells Code Collection Complement DNA Sequence Alteration DRADA2b protein Data Data Set Double-Stranded RNA Enzymes Epithelial Future Gene Expression Genes Genetic Transcription Genomics Goals Heterogeneity Human Immune Response Genes Immune response Immunotherapy Inosine Interferon Activation Interferons Label Malignant Neoplasms Mammals Mesenchymal Cell Neoplasm Methodology Methods Modification Molecular Mutation Natural Immunity Nucleotides Organism Outcome Pathway interactions Patients Pattern Phenotype Proteins Proteomics RNA RNA Editing RNA Sequences RNA analysis RNA-Binding Proteins Regulation Reporting Research Role Sampling Site Structure Technology Transcript Untranslated RNA Validation Work cancer cell cancer risk cancer type cell type genetic architecture genomic RNA human disease immunoregulation insertion/deletion mutation insight mRNA Stability neuropsychiatric disorder novel prevent response secondary analysis success transcriptome transcriptome sequencing transcriptomics treatment response tumor

项目摘要

Project Summary This project aims to better understand the regulation and function of RNA editing in cancer through analysis of existing omics data sets. RNA editing is a prevalent type of RNA modification where the RNA sequences are altered through insertion, deletion or substitution of nucleotides. In mammals, the most common type of RNA editing is adenosine to inosine (A-to-I) editing. Catalyzed by the ADAR enzymes, A-to-I editing is the most prevalent type of RNA editing in human, occurring in the majority of human transcripts. In the past few decades, great progress was made to understand the critical function of a small number of A-to-I editing sites in cancer-related genes, most of which alter protein-coding sequences. Owing to the recent advances in RNA-sequencing (RNA-seq) technologies and bioinformatic methodologies, an unprecedented number of A-to-I editing sites have been cataloged for various organisms. Importantly, widespread aberrant RNA editing has been reported in a number of cancer types. In addition, increasing evidence supports that ADAR and RNA editing levels are associated with patient survival or response to therapy. However, many questions remain, the most significant ones including the unclear mechanisms through which ADAR and RNA editing contribute to cancer-related pathways and the unknown regulatory mechanisms underlying aberrant RNA editing in cancer. In this project, we propose to extend our recent successes at developing and applying bioinformatic approaches in RNA editing studies to address the above challenges. We will capitalize on the large collection of RNA-seq data sets derived from different types of cancer samples. We will develop and apply novel methodologies to make full use of these data sets, complemented by further bioinformatic prediction and experimental validations, to predict and validate the molecular function of RNA editing and related regulatory mechanisms. This work will allow a previously unattained level of understanding of the molecular basis of RNA editing and provide new insights to the involvement of RNA editing in human cancer.

项目总结